An ongoing phase 2 trial is providing additional data on BV retreatment in patients with classical Hodgkin's lymphoma, sALCL, or other cd30-positive PTCL (NCT03947255) [107]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.